肝癌患者血清高迁移率族蛋白B1的表达及与p53和临床病理的相关性

[目的] 探讨肝癌血清HMGB-1的表达及与p53的相关性和临床病理的联系。[方法] 酶联免疫吸附剂测定法(ELISA)检测20例肝细胞癌、20例肝内胆管细胞癌和20例健康志愿者血清HMGB-1和p53表达。 [结果] 血清HMGB-1在肝细胞癌组(83.8±17.4ng/ml)和胆管细胞癌组(95.9±21.4ng/ml)表达都高于健康对照组(8.4±2.6ng/ml)，差异均有统计学意义(p<0.05)；血清p53在肝细胞癌组(251.0±45.6pg/ml)和胆管细胞癌组(267.8±47.4pg/ml)表达都高于健康对照组(160.0±28.4pg/ml)，差异均有统计学意义(p<0.05)；血清HMGB-1和p53水平与患者年龄、性别、肿瘤大小和数目没有明显相关性，差异无统计学意义（p>0.05），与肿瘤TNM分期、分化程度、淋巴转移情况相关，差异有统计学意义（p<0.05）；HMGB-1和p53的表达在肝细胞癌组和肝内胆管细胞癌组血清中均呈正相关(r=0.6603，p<0.05；r=0.6142，p<0.05)。[结论] 肝癌血清HMGB-1的表达与p53具有相关性，二者共同影响肝癌临床病理。

Serum HMGB-1 level and its correlation with p53 and clinical pathology in patients with liver cancer

Objective To investigate the serum level of high mobility group box-1(HMGB-1) in patients with liver cancer and its correlation with p53 and clinical pathological features of liver cancer. Methods Serum levels of HMGB-1 and p53 were determined by ELISA in 20 patients with hepatocellular carcinoma, 20 with cholangiocellular carcinoma and 20 healthy volunteers. Results Serum HMGB-1 levels in hepatocellular carcinoma patients ([83.8±17.4] ng/ml) and cholangiocellular carcinoma patients ([95.9±21.4] ng/ml) were significantly higher than that in the healthy volunteers ([8.4±2.6] ng/ml, P<0.05). Serum p53 levels in hepatocellular carcinoma patients ([251.0±45.6] pg/ml) and cholangiocellular carcinoma patients ([267.8±47.4] pg/ml) were also significantly higher than that in the healthy volunteers ([160.0±28.4] pg/ml, P<0.05). Serum HMGB-1 level was positively correlated with the serum p53 level in the hepatocellular carcinoma patients (r=0.660 3, P<0.05) and cholangiocellular carcinoma patients (r=0.614 2, P<0.05). Serum HMGB-1 and p53 levels were not correlated with the age, gender, tumor size, or number of tumors (P>0.05), but were correlated with the TNM stage, differentiation degree and metastasis status (P<0.05).Conclusion Serum HMGB-1 level is positively correlated with p53, and both HMGB-1 and P53 influence the pathogenesis of liver cancer.